GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » YIFAN PHARMACEUTICAL CO LTD (SZSE:002019) » Definitions » Forward PE Ratio

YIFAN PHARMACEUTICAL CO (SZSE:002019) Forward PE Ratio : 0.00 (As of May. 26, 2024)


View and export this data going back to 2004. Start your Free Trial

What is YIFAN PHARMACEUTICAL CO Forward PE Ratio?

YIFAN PHARMACEUTICAL CO's Forward PE Ratio for today is 0.00.

YIFAN PHARMACEUTICAL CO's PE Ratio without NRI for today is 35.00.

YIFAN PHARMACEUTICAL CO's PE Ratio for today is 0.00.


YIFAN PHARMACEUTICAL CO Forward PE Ratio Historical Data

The historical data trend for YIFAN PHARMACEUTICAL CO's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YIFAN PHARMACEUTICAL CO Forward PE Ratio Chart

YIFAN PHARMACEUTICAL CO Annual Data
Trend
Forward PE Ratio

YIFAN PHARMACEUTICAL CO Quarterly Data
Forward PE Ratio

Competitive Comparison of YIFAN PHARMACEUTICAL CO's Forward PE Ratio

For the Drug Manufacturers - General subindustry, YIFAN PHARMACEUTICAL CO's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


YIFAN PHARMACEUTICAL CO's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, YIFAN PHARMACEUTICAL CO's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where YIFAN PHARMACEUTICAL CO's Forward PE Ratio falls into.



YIFAN PHARMACEUTICAL CO Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


YIFAN PHARMACEUTICAL CO  (SZSE:002019) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


YIFAN PHARMACEUTICAL CO Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of YIFAN PHARMACEUTICAL CO's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


YIFAN PHARMACEUTICAL CO (SZSE:002019) Business Description

Traded in Other Exchanges
N/A
Address
No. 50 Qinshan, Jincheng, Lin'an Economic Development Zone, Hangzhou, Zhejiang, CHN, 311300
YIFAN PHARMACEUTICAL CO LTD is a China-based company engaged in pharmaceutical innovation and manufacturing. The company focuses its activities on key areas like macromolecular biologics, high-value pharmaceuticals, and differentiated traditional Chinese medicines. The products of the company are F-627 for Neutropenia and Parkinson's disease, F-652 for acute alcoholic hepatitis, GvHD and acute pancreatitis and F-899 for growth deficiency. The company's products are sold in China and internationally.
Executives
Ye Yi Qun Director
Zhang Da Wei Executives
Geng Yu Hong Executives
Feng De Qi Directors, Directors, and Executives
Zhou Ben Yu Director
Lin Xing Directors, executives
Yu Hai Xia Executives
Cheng Xian Feng Directors, executives
Xu Guo Han Supervisors
Cao Shi Mei Director
Lin Guan Yu Director
Zhang Lian Chun Executives
Guo Xin Fu Director
Zheng Shi Ming Supervisors
Yin Hang Hua Executives

YIFAN PHARMACEUTICAL CO (SZSE:002019) Headlines

No Headlines